Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

被引:0
作者
Qian Li
Xin Li
Chong Ye
Miaomiao Jia
Tianmei Si
机构
[1] Peking University Sixth Hospital,
[2] Peking University Institute of Mental Health,undefined
[3] NHC Key Laboratory of Mental Health (Peking University),undefined
[4] National Clinical Research Centre for Mental Disorders (Peking University Sixth Hospital),undefined
[5] Xi’an Janssen Pharmaceutical Ltd,undefined
来源
BMC Psychiatry | / 24卷
关键词
Schizophrenia; Antipsychotic agents; Paliperidone palmitate; Systematic review;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 263 条
[1]  
El Khoury A(2019)Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization Curr Med Res Opin 35 2159-68
[2]  
Patel C(2022)A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China BMC Psychiatry 22 95-74
[3]  
Huang A(2021)The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study Adv Ther 38 1958-62
[4]  
Wang L(2014)Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies Patient Relat Outcome Meas 5 43-18
[5]  
Bashyal R(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-78
[6]  
Liu J(2020)Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: a veterans health administration claims analysis Curr Ther Res Clin Exp 92 100587-98
[7]  
Wang Q(2020)Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology J Psychopharmacol (Oxford, England) 34 3-64
[8]  
Su L(2020)Adherence to Oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis CNS Drugs 34 579-701
[9]  
Yang L(2004)Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors Schizophrenia Bull 30 255-44
[10]  
Zou L(2018)Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence Journal of psychopharmacology (Oxford, England). 32 691-45